24/7 Market News Snapshot 16 July, 2025 – Cue Biopharma, Inc. (NASDAQ:CUE)

July 16, 2025

DENVER, Colo., 16 July, 2025 (www.247marketnews.com) – (NASDAQ:CUE) are discussed in this article.
Cue Biopharma, Inc. is experiencing significant momentum in the market, marked by an impressive 41% increase in intraday trading. Opening at $0.70, shares have surged to $0.987, with a trading volume tallying 2.61 million shares, reflecting heightened investor interest. This rally follows a previous closing price of $0.70, indicative of a bullish trend that is captivating market observers and stakeholders keenly monitoring the biotech firm’s developments.

Simultaneously, Cue Biopharma has made strides in advancing its immunotherapy solutions, particularly highlighting the efficacy of CUE-101, part of the company’s innovative CUE-100 series aimed at selectively targeting disease-specific T cells for patients afflicted with advanced cancers. Recent clinical data reveals a compelling overall response rate (ORR) of 50% among patients exhibiting a combined positive score (CPS) of ≥1, with significant outcomes noted in those with lower CPS values as well.

A standout case amongst these findings is a patient suffering from recurrent metastatic HPV-positive head and neck squamous cell carcinoma (HNSCC), who demonstrated a complete response following CUE-101 treatment in conjunction with pembrolizumab (KEYTRUDA®). This patient maintained stable disease for nearly two years before achieving considerable tumor reductions, emphasizing the differentiating efficacy of CUE-101 compared to conventional cytotoxic therapies.

The trial results also point to a noteworthy 12-month overall survival rate of 88%, far surpassing the 57% survival observed with pembrolizumab in historical trials, with the median overall survival period standing at an encouraging 32 months. Dan Passeri, the Chief Executive Officer of Cue Biopharma, expressed optimism about CUE-101’s potential to redefine treatment protocols for HPV-related cancers and beyond. The company’s commitment to advancing its Immuno-STAT® platform underscores its mission to enhance cancer treatment outcomes while reducing adverse effects.

Related news for (CUE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.